Why are my ringworm lesions increasing despite taking oral terbinafine 250 mg daily, and what should I do?

Increasing Ringworm Lesions Despite Terbinafine: Evaluation and Management

Your ringworm lesions are likely increasing because terbinafine may be ineffective against the specific dermatophyte causing your infection—most commonly this occurs with Microsporum species or emerging terbinafine-resistant strains, and you should obtain mycological testing immediately to identify the organism and switch to appropriate therapy.

Understanding Treatment Failure

When ringworm lesions worsen or spread despite oral terbinafine 250 mg daily, several critical factors must be evaluated systematically 1:

Primary Causes to Consider

Species-specific resistance patterns:

• Terbinafine is highly effective against Trichophyton species (T. tonsurans, T. violaceum, T. soudanense) but has significantly lower efficacy against Microsporum species (M. canis, M. audouinii) 1
• For Microsporum infections, the minimum inhibitory concentration for terbinafine can exceed the maximum concentration achieved in tissue, leading to treatment failures 1
• Terbinafine is not excreted in sweat or sebum adequately to reach surface arthroconidia in Microsporum infections 1

Emerging terbinafine resistance:

• Terbinafine-resistant Trichophyton indotineae (formerly T. mentagrophytes genotype VIII) is spreading globally, including in Europe 2
• Resistance is mediated by mutations in the squalene epoxidase (SQLE) gene, with documented mutations including I479T and I479V 3
• These resistant strains can show MICs ranging from 0.5 to ≥16 μg/mL 3, 2

Other treatment failure factors:

• Non-compliance with medication 1
• Suboptimal drug absorption 1
• Reinfection from untreated contacts or contaminated fomites 1

Immediate Action Steps

1. Obtain Mycological Testing

You must obtain proper diagnostic testing before changing therapy 1:

• Collect skin scrapings from the active border of lesions via scalpel scraping, brush, or swab 1
• Request both microscopy (KOH preparation) AND culture 1
• Specifically request antifungal susceptibility testing (AFST) and SQLE gene sequencing if available, given emerging resistance patterns 3, 2

2. Switch Antifungal Therapy Based on Organism

If Microsporum species is identified or suspected:

• Switch to griseofulvin 15-20 mg/kg/day (or 1 g/day if >50 kg) for 6-8 weeks 1
• Griseofulvin is significantly more effective than terbinafine for Microsporum infections 1

If Trichophyton species with suspected or confirmed terbinafine resistance:

• Switch to itraconazole 200 mg daily for 4 weeks, or 5 mg/kg/day 1, 3
• Itraconazole has activity against both Trichophyton and Microsporum species 1
• For confirmed resistant strains, SUBA-itraconazole (super bioavailability formulation) may be required with prolonged therapy 3
• Alternative: voriconazole or fluconazole in refractory cases 1

If organism identification is delayed:

• Given treatment failure, it is reasonable to switch to itraconazole empirically while awaiting culture results 1

3. Assess for Compliance and Absorption Issues

• Verify you are taking terbinafine with food to enhance absorption 4
• Confirm no missed doses 4
• Check for drug interactions (rifampicin decreases levels, cimetidine increases levels) 1

4. Evaluate for Reinfection Sources

• Screen household contacts and close contacts for infection, particularly if Trichophyton tonsurans is identified 1
• Treat asymptomatic carriers with high spore loads 1
• Decontaminate fomites (clothing, bedding, towels) 1

Critical Pitfalls to Avoid

Do not continue ineffective therapy:

• If there is no clinical improvement after 2-4 weeks of terbinafine, continuing the same medication will not help 1
• Prolonging terbinafine treatment does not improve efficacy against resistant organisms 1

Do not use combination antifungal-corticosteroid products:

• These can worsen dermatophyte infections and contribute to resistance patterns 5
• Corticosteroids suppress inflammation temporarily but allow fungal proliferation

Do not assume higher terbinafine doses will overcome resistance:

• Recent evidence shows that increasing terbinafine from 250 mg to 500 mg daily does not significantly improve cure rates (20% vs 33.3%, P=0.82) 6
• Higher doses may increase side effects without added benefit against resistant strains 6

Expected Timeline and Monitoring

• Re-evaluate clinically at 2-4 weeks after switching therapy 1
• If clinical improvement occurs but mycology remains positive, continue therapy for an additional 2-4 weeks 1
• The endpoint of treatment is mycological cure, not just clinical improvement 1
• Repeat mycological sampling until clearance is achieved 1

When to Consider Specialist Referral

Refer to dermatology or infectious disease if:

• No response to second-line therapy (itraconazole or griseofulvin) 1
• Confirmed terbinafine-resistant organism requiring specialized antifungal regimens 3, 2
• Extensive disease involving large body surface area 5
• Immunocompromised state 5